Standard Biotools is trading at $0.70, up 5.74% in after-hours trading, with no new company-specific announcement or credible August 18, 2026 catalyst identified.
- Latest confirmed company news remains the August 5 second-quarter report, which included weaker revenue and a withdrawn full-year outlook.
- That report is stale and does not clearly explain the gain.
- Broader markets declined sharply, but the move does not directly align with that session-wide trend.